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Background. Diarrhea is the third leading cause of child death in Zambia. Up to one-third of diarrhea cases resulting in hos-
pitalization and/or death are caused by vaccine-preventable rotavirus. In January 2012, Zambia initiated a pilot introduction of the
Rotarix live, oral rotavirus vaccine in all public health facilities in Lusaka Province.
Methods. Between July 2012 and October 2013, we conducted a case-control study at 6 public sector sites to estimate rotavirus
vaccine effectiveness (VE) in age-eligible children presenting with diarrhea. We computed the odds of having received at least 1 dose
of Rotarix among children whose stool was positive for rotavirus antigen (cases) and children whose stool was negative (controls).
We adjusted the resulting odds ratio (OR) for patient age, calendar month of presentation, and clinical site, and expressed VE as
(1 – adjusted OR) × 100.
Results. A total of 91 rotavirus-positive cases and 298 rotavirus-negative controls who had under-5 card-confirmed vaccination
status and were ≥6 months of age were included in the case-control analysis. Among rotavirus-positive children who were age-
eligible to be vaccinated, 20% were hospitalized. Against rotavirus diarrhea of all severity, the adjusted 2-dose VE was 26% (95%
confidence interval [CI], −30% to 58%) among children ≥6 months of age. VE against hospitalized children ≥6 months of age
was 56% (95% CI, −34% to 86%).
Conclusions. We observed a higher point estimate for VE against increased severity of illness compared with milder disease, but
were not powered to detect a low level of VE against milder disease.
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Globally, an estimated 751 000 deaths in children <5 years of
age were caused by diarrhea in 2010, making it the second lead-
ing cause of death in children <5 years of age [1]. Africa ac-
counts for 46% of the world’s child diarrheal deaths but only
13% of its population [2]. Rotavirus infection caused approxi-
mately 37% of diarrhea-attributable deaths worldwide in 2008
[3].Diarrhea is the third leading cause of child death in Zambia.
In 2009, Zambia reported an annual diarrheal burden of 10 mil-
lion episodes among its 2.4 million children <5 years of age, re-
flecting an average of >2 episodes per child per year [4]. Up to
one-third of diarrhea cases resulting in hospitalization and/or
death are caused by vaccine-preventable rotavirus [5–7].
Research from other countries, particularly in Latin America
and several African countries including South Africa andMalawi,
has shown the promise of the rotavirus vaccine in reducing child
deaths attributable to rotavirus, incident severe gastroenteritis,
and related hospital admission [8–11].
In January 2012 the Zambian government, in partnership with
the Centre for Infectious Disease Research in Zambia (CIDRZ)
and Ark, initiated a 2-year, pilot introduction of the Rotarix
live, oral rotavirus vaccine in all public health facilities in Lusaka
Province. Details of this program rollout are available elsewhere
[12]. In November 2013, following this sucessful pilot, Zambia
became the 17th Gavi-eligible country to introduce the vaccine
nationally. The recommended schedule for Rotarix in Zambia
aligned with the standard Expanded Programme on Immuniza-
tion (EPI) visits with 2 doses recommended at 6 and 10 weeks of
age, but allowing the first dose to be administered between 6 and
20 weeks of age. The pentavalent diphtheria-tetanus-pertussis
(DTP), Haemophilus influenzae type b (Hib), and hepatitis B
(HepB) vaccine has been a part of Zambia’s EPI since 2005,
with the first 2 doses recommended at 6 and 10 weeks of age,
making it a good comparator for vaccine uptake.
As part of a larger evaluation of diarrhea-related child illness in
Lusaka and Ndola, Zambia, we conducted a case-control study to
evaluate the effectiveness of the rotavirus vaccine in this popula-
tion. Here we present vaccine effectiveness (VE) findings from the
regional pilot vaccine introduction in Lusaka Province, Zambia.
METHODS
Study Sites
This study was conducted between July 2012 andOctober 2013 at
6 sentinel, public health facilities in Lusaka Province, which were
included in the pilot vaccine rollout. Three facilities were in
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Lusaka District, the most densely populated, urban district in
Zambia, and 1 additional facility was in each of the 3 remaining
districts—Kafue, Chongwe, and Luangwa—which contain a
lower-density, more rural population. Facilities were purposively
selected. We selected facilities with inpatient departments, suffi-
cient under-5 patient volume, space to support study activities,
and geographical consistency with the pilot vaccine rollout.
Screening, Enrollment, and Study Procedures
The study team conducted active surveillance for children pre-
senting with diarrhea at each of the study sites. A child was con-
sidered eligible if they met the following criteria: age 0–59
months; admitted to the inpatient department or under care in
the outpatient department at the time of screening; and caregiver
verbal confirmation of child presenting with diarrhea (defined as
the passing of ≥3 abnormally loose stools in the past 24 hours).
Additionally, children were determined to be eligible if there was
an indication of potentially severe diarrhea by confirmation of at
least 1 of the following symptoms assessed through physical ex-
amination by the study nurse or verbal confirmation by the care-
giver: sunken eyes, loss of normal skin turgor, intravenous
rehydration prescribed/administered, blood in stool, and hospi-
talization for diarrhea or dysentery. Study nurses targeted enroll-
ment of younger children, attempting to enroll approximately
two-thirds of the sample from children <24 months of age.
As part of the larger evaluation of diarrheal disease, caregivers
who voluntarily consented to participate completed a 3-part as-
sessment: part 1 immediately upon enrollment, targeted to occur
as soon as possible after the child entered care; part 2 at the child’s
discharge from health services (same day if an outpatient); and
part 3 thirty days after enrollment. Part 1 data utilized for the
VE evaluation included individual and household demographics
(eg, age, sex, caregiver education level, family size), maternal
health status, the child’s symptoms, history and treatment of
the current illness, and child health background. The child’s vac-
cination history and growth trajectory were recorded from the
under-5 card (child health record). If the under-5 card was un-
available, verbal confirmation of vaccination status was requested
from the caregiver. The child’s health status during the study as-
sessment was documented based on a combination of health fa-
cility record review for the current visit and a clinical examination
of the child by the study nurse. A stool sample was collected for
laboratory assessment. Part 2 included a review of the child’s
health status and treatment received while in care. Part 3 deter-
mined child vital status at 30 days after enrollment.
A combination of parts 1 and 2 provided the 7 components
required for assessment of the child’s disease severity using a Ves-
ikari score (diarrheal stool and vomiting frequency and duration
based on caregiver report, treatment based on admission status,
temperature, and dehydration based on clinical assessment) [13].
Stool specimens were refrigerated and transported from the
study sites to the CIDRZ laboratory. They were tested for
rotavirus antigen by enzyme immunoassay (EIA) using a
monoclonal antibody solid phase sandwich. The Meridian Ro-
taclone EIA kit for the detection of rotavirus antigen in fecal
samples (catalog number 696004) was used for the analysis.
The study was approved by research ethics authorities at the
Zambian Ministry of Health, the University of Zambia, the Uni-
versity of Alabama at Birmingham, and the University of North
Carolina at Chapel Hill.
Vaccine Effectiveness Analysis
Children who presented with moderate to severe diarrhea and
who were age-eligible to have received rotavirus vaccine and had
under-5 card-confirmed vaccination records were included in the
VE analysis. Children whose stool specimen tested positive for ro-
tavirus by EIA were classified as cases, whereas those with EIA-
negative results were controls. A child was considered age-eligible
for the vaccine if the rotavirus vaccine was available in the child’s
health facility when the child was 6 weeks of age. A child was con-
sidered vaccinated if she or he received a minimum of 1 dose of
vaccine at least 14 days before presentation to the study site.
Data Processing and Analysis
Study data were collected on paper forms by trained research
nurses stationed at the study clinic sites, who conducted quality
control on the data they collected. Centrally, the data were again
checked for quality by the study Quality Control Nurse and in-
vestigators before they were entered onto a database constructed
in SQL 2008 and Access 2010. Severity of rotavirus diarrhea was
classified using the 20-point Vesikari scoring system. EIA
results were entered by a laboratory technician into a separate
database that was merged with other study data using the par-
ticipant’s study-assigned unique identification number.
Statistical Analysis
Sociodemographic and clinical characteristics of cases and con-
trols were compared using χ2 analyses for categorical variables.
For continuous variables, medians were compared using the
Wilcoxon rank-sum test.We reviewed age at vaccination, rotavirus
vaccine coverage by rotavirus result, and rotavirus vaccine uptake
compared to pentavalent vaccine (DTP-Hib-HepB) uptake.
We used unconditional logistic regression, controlling for
month and year of birth, month and year of admission, and
clinical site to calculate the adjusted odds ratio (aOR) for rota-
virus vaccination compared to no vaccination. To account for
residual confounding related to age given the small sample
size, we restricted our results to children aged ≥6 months. VE
was expressed as (1 – aOR) × 100.
RESULTS
Presentation of Rotavirus Diarrhea
Among all 1506 children <5 years of age enrolled in the study in
Lusaka, rotavirus detection between July 2012 and October
2013 showed 2 peaks, 1 around October (a hot, dry month
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Figure 1. Rotavirus detection among children <5 years of age, July 2012–October 2013.
Figure 2. Inclusion flow chart. Abbreviation: EIA, enzyme immunoassay.
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before the rainy season) and 1 in June (a cool, dry month after
the rainy season) (Figure 1).
Vaccine Effectiveness Analysis Sample
We excluded 904 children enrolled in diarrhea surveillance
from the VE analysis, of whom 885 (98%) were excluded
because they were age-ineligible to receive vaccine either be-
cause they were enrolled in the study prior to vaccine rollout
at their district or were too old to receive the vaccine. A total
of 125 rotavirus-positive cases and 404 rotavirus-negative con-
trols that had under-5 card-confirmed vaccination status were
included in the case-control analysis (Figure 2).
Table 1. Comparison of Cases and Controls Age-Eligible for Rotavirus Vaccine (≤6 Weeks of Age at Time of Vaccine Introduction)
Characteristic
Rotavirus-Positive Cases (n = 144),
No. (%)
Rotavirus-Negative Controls (n = 458),
No. (%)
P
Value
Age, mo, median (range) 8 (0–18) 8 (0–21) .54
Male sex 68/140 (49) 217/438 (50) .84
Any chronic disease 4/143 (3) 25/442 (6) .17
Heart disease 0/139 (0) 1/421 (0.2) .80
Diabetes 0/138 (0) 2/429 (0.5) .66
Asthma 0/141 (0) 2/438 (0.5) .22
Epilepsy 1/141 (1) 3/438 (1) .98
Malnutrition 2/141 (1) 19/434 (4) .22
Human immunodeficiency virus 1/137 (1) 3/424 (1) .95
Tuberculosis 1/138 (1) 0/423 (0) .21
Premature birth 6/139 (4) 17/426 (4) .71
Respondent’s relationship to child .04a
Mother 135/143 (94) 444/451 (98)
Father 5/143 (4) 3/451 (1)
Grandmother 1/143 (1) 2/451 (0.4)
Aunt 2/143 (1) 1/451 (0.2)
Other relative guardian 0/143 (0) 1/451 (0.2)
Respondent’s education level .69
Primary 62/137 (45) 195/380 (51)
Secondary 69/137 (50) 165/380 (43)
Tertiary 1/137 (1) 5/380 (1)
Other/unknown/refused 5/137 (4) 16/380 (4)
Mother’s current health .69
Alive, well 136/139 (98) 411/424 (97)
Alive, ill 2/139 (1) 11/424 (3)
Dead 1/139 (1) 2/424 (4)
No. of siblings .22
0 38/138 (29) 130/425 (31)
1 35/138 (25) 117/425 (28)
2 31/138 (22) 90/425 (21)
3 13/138 (9) 52/425 (12)
4–6 21/138 (15) 33/425 (8)
≥7 0/138 (0) 1/425 (0.2)
No. of rooms in child’s home .92
<2 79/139 (57) 228/402 (67)
2–4 38/139 (27) 105/402 (26)
≥5 22/139 (16) 69/402 (17)
Toilet facility in child’s home .96
Flush/pour to sewer or septic tank 39/139 (28) 110/403 (27)
Flush/pour to pit latrine or ventilated improved pit latrine 16/139 (12) 50/403 (12)
Pit latrine with slab or without slab (open pit) 84/139 (60) 243/403 (60)
Hanging toilet/hanging latrine or no facility (bush/field) 0/139 (0) 0/403 (0)
Median expenditure made by child’s household on food in past 30 d
(range)b
600 (50–1 000 000) 400 (20–1 500 000) .002a
Median expenditure made by child’s household on nonfood items in
past 30 d (range)b
450 (12–1 000 000) 300 (10–1 500 000) .02a
a Statistically significant at the .05 level.
b No. of children with nonmissing data on household food expenditure: 93 for rotavirus positive and 258 for rotavirus negative; No. of children with nonmissing data on household nonfood
expenditure: 82 for rotavirus positive and 227 for rotavirus negative.
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Table 2. Clinical Characteristics of Children Age-Eligible for Rotavirus Vaccine (≤6 Weeks of Age at Time of Vaccine Introduction)
Characteristic Rotavirus Positive (n = 144), No. (%) Rotavirus Negative (n = 458), No. (%) P Value
Duration of diarrhea .006a
1–4 d 91/140 (65) 309/441 (70)
5 d 24/140 (17) 35/441 (8)
≥6 d 25/140 (18) 97/441 (22)
Maximum No. of diarrhea episodes in 24 h .008a
1–3 59/141 (42) 245/446 (55)
4–5 67/141 (48) 177/446 (40)
≥6 15/141 (11) 24/446 (5)
Vomiting (% yes) 80/143 (56) 155/451 (34) <.001a
If yes, duration of vomiting .008a
1 d 6/80 (8) 22/151 (15)
2 d 27/80 (34) 72/151 (48)
≥3 d 47/80 (59) 57/151 (38)
If yes, maximum No. of vomiting episodes in 24 h .08
1 2/78 (3) 14/151 (9)
2–4 68/78 (87) 129/151 (85)
≥5 8/8078 (10) 8/151 (5)
Highest recorded temperature .13
<37°C 75/143 (52) 278/458 (61)
37°C–<38.5°C 53/143 (37) 125/458 (27)
38.5°C–<38.9°C 3/143 (2) 17/458 (4)
≥39°C 12/143 (8) 36/458 (8)
Capillary refill time .11
Normal (<2 sec) 119/142 (84) 407/453 (90)
Sluggish (2–3 sec) 22/142 (15) 42/453 (9)
Delayed (>3 sec) 1/142 (1) 4/453 (1)
Child’s skin turgor at admission .53
Goes back quickly (immediately) 60/139 (43) 214/451 (47)
Goes back slowly (1–2 sec) 75/139 (54) 229/451 (51)
Goes back very slowly (>2 sec) 4/139 (3) 8/451 (2)
Buccal mucosa/lips .80
Moist 22/143 (15) 80/454 (18)
Dry 119/143 (83) 369/454 (81)
Parched/cracked 2/143 (1) 5/454 (1)
Eyes .81
Normal 52/143 (36) 152/455 (33)
Deep set 13/143 (9) 43/455 (9)
Sunken 78/143 (55) 260/455 (57)
Condition on arrival .02a
Normal/appropriate 45/143 (31) 180/453 (39)
Fussy/restless but consolable 75/143 (52) 236/453 (52)
Severely irritable/inconsolable 18/143 (13) 36/453 (8)
Lethargic/somnolent 5/143 (4) 4/453 (1)
Obtunded/comatose 0/143 (0) 0/453 (0)
Child’s thirst status at admission .75
Drank normally, not thirsty 121/136 (89) 371/426 (86)
Thirsty, drank eagerly 12/136 (9) 45/426 (10)
Drank poorly, not able to drink 1/136 (1) 2/426 (0.4)
Unknown 2/136 (1) 46/426 (3)
Hospitalized (% yes) 29/144 (20) 93/458 (20) .97
Vesikari score <.001a
≤10 (mild) 80/137 (58) 349/433 (81)
11–14 (moderate) 47/137 (34) 71/433 (16)
≥15 (severe) 10/137 (7) 13/433 (3)
a Statistically significant at the .05 level.
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Characteristics of Cases and Controls
Cases and controls were similar in age, sex, chronic disease
prevalence, and household demographics. The rotavirus
cases were more often brought in by a caregiver other than
their mother and reported higher median expenditure on
food and nonfood items in the child’s household 30 days
prior to the child’s presentation at the health facility
(Table 1).
Compared to antigen-negative children, those who were rota-
virus positive had more severe diarrhea (including a greater du-
ration and maximum number of diarrhea episodes), were more
likely to have vomiting and for a longer duration, were in worse
clinical condition on arrival at the facility, and had a higher Ves-
ikari score compared to controls (Table 2). Only 20% of cases
and controls were hospitalized.
Vaccine Coverage and Age Appropriateness
Vaccine coverage among cases and controls was high, at 70% for
at least 1 dose and 58% for 2 doses of rotavirus vaccine. Al-
though cases had lower pentavalent vaccine coverage, there
were no significant differences between cases and controls for
rotavirus vaccine coverage (Table 3).
Rotavirus vaccination timing was consistent with recommend-
ed schedules, compared to pentavalent vaccine administration
(Figure 3). The median age at rotavirus and pentavalent vaccine
administration was 6 weeks for dose 1 and 11 weeks for dose
2. Among children vaccinated against rotavirus, 79% received
their first dose within 2 weeks of the recommended age for vac-
cination and 64% received their second dose within 2 weeks of
the recommended age. Among children receiving pentavalent
vaccine, 84% and 71% received their first and second doses, re-
spectively, within 2 weeks of the recommended age.
Vaccine Effectiveness, Children Aged ≥6 Months
Against rotavirus diarrhea of all severity, the adjusted 2-dose VE
among children ≥6 months of age was 26% (95% confidence
interval [CI], −30% to 58%). Against rotavirus diarrhea that
required hospitalization, it was 56% (95% CI, −34% to 86%).
Table 3. Vaccine Coverage of Children Age-Eligible for Rotavirus
Vaccine by Rotavirus Test Result
Vaccination Status
Rotavirus Positive
(n = 144),
No. (%)
Rotavirus Negative
(n = 458),
No. (%)
P
Value
Verified vaccination
status
.65
Card seen 125 (87) 404 (88)
Card not seen 19 (13) 54 (12)
Coverage among children with card-verified vaccination status
Rotavirus vaccine n = 125 n = 404 .79
0 doses 39 (31) 122 (30)
1 dose 16 (13) 44 (11)
2 doses 70 (56) 238 (59)
Pentavalent
vaccine
n = 125 n = 404 .02a
0 doses 8 (6) 12 (3)
1 dose 6 (5) 21 (5)
2 doses 24 (19) 44 (11)
3 doses 87 (70) 327 (81)
a Statistically significant at the .05 level.
Figure 3. Age at rotavirus (Rota) and pentavalent (Penta) vaccination among children age-eligible to receive rotavirus vaccine.
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VE against very severe rotavirus (Vesikari ≥15) for children
with 2 doses was 48% (95% CI, −163% to 90%) (Table 4).
DISCUSSION
Our study is the first report on rotavirus VE in Zambia, in the
context of a regional pilot project. We observed a higher point
estimate for VE among children with more severe illness com-
pared with children with milder illness, consistent with what
has been reported elsewhere [14–16]. For children ≥6 months
of age who were hospitalized, we observed 57% effectiveness
with at least 1 dose of vaccine.
Among age-eligible children, more children received the pen-
tavalent vaccine, to which the rotavirus vaccine timing was syn-
chronized, than the rotavirus vaccine. This likely represents the
challenges that the health system experienced in supply and
training of staff to support new vaccine rollout, even with the
dedicated support accompanying the pilot [12]. This suggests
that additional research on ways to limit missed opportunities
for rotavirus vaccine administration would be useful as rotavi-
rus becomes part of the routine immunization program of ad-
ditional countries. It is unclear, however, why cases have lower
pentavalent coverage than controls.
Interestingly, although the study was conducted in a period
just over 1 calendar year, our results confirm the typical trend
on the seasonality of rotavirus disease as has been reported else-
where; 1 peak in the cool dry seasons (May–July) and a second,
but smaller peak in the hot dry season (September–
October) [6, 17]. Future research characterizing trends in
under-5 diarrhea seasonality may demonstrate shifts based on
vaccination effects and the impact of other etiologic agents of
diarrhea.
The overall trend of VE, with an aOR ranging from 17% to 60%
for at least 1 dose, is consistent with other studies from developing
countries [14, 15, 18]. These findings support prior reports of the
relatively lower VE of live oral vaccines in low- to middle-income
countries such as Zambia, compared with more developed coun-
tries [14, 19]. Effective public health efforts to reduce diarrhea
must continue to emphasize the importance of other preventive
practices alongside vaccination to minimize cases.
The study is limited by its small sample size of severe rotavi-
rus cases and its high vaccination coverage. Only 20% of the
children enrolled through the outpatient surveillance required
hospitalized care in our study. Rotavirus is the most common
cause of severe gastroenteritis in young children and accounts
for a higher proportion of cases among children hospitalized
for acute gastroenteritis than among children requiring outpa-
tient care. Furthermore, rotavirus vaccines are more effective in
preventing severe disease than mild disease. Whereas 23% of
all diarrhea cases in the study were severe and 4% very severe,
the study also included mild diarrhea. Thus, given the high pro-
portion of children receiving outpatient care enrolled in our
study, we were not powered to detect a low-level VE against
Table 4. Vaccine Effectiveness by Dose of Rotavirus Vaccine Among Children Aged ≥6 Months
Doses of Rotavirus Vaccinea Rotavirus Positive Rotavirus Negative
Unadjusted VE, %
(95% CI)
Adjusted VEb, %
(95% CI)
Cases, all severity n = 91 n = 298
0 doses 32 (35) 88 (30) ref ref
1 dose 7 (8) 28 (9) 31 (−73, 73) 29 (−82, 73)
2 doses 52 (57) 182 (61) 21 (−31, 53) 26 (−30, 58)
At least 1 dose 59 (65) 210 (70) 23 (−27, 53) 27 (−27, 58)
Hospitalized casesc n = 18 n = 298
0 doses 9 (50) 88 (30) ref ref
1 dose 1 (6) 28 (9) 65 (−188, 96) 62 (−261, 96)
2 doses 8 (44) 182 (61) 57 (−15, 84) 56 (−34, 86)
At least 1 dose 9 (50) 210 (70) 58 (−9, 84) 57 (−27, 85)
Cases with Vesikari score ≥11c n = 35 n = 298
0 doses 11 (31) 88 (30) ref ref
1 dose 1 (3) 28 (9) 71 (−131, 96) 77 (−99, 97)
2 doses 23 (66) 182 (61) −1 (−117, 53) 5 (−125, 59)
At least 1 dose 24 (69) 210 (70) 9 (−95, 57) 17 (−91, 64)
Cases with Vesikari score≥ 15c n = 8 n = 298
0 doses 4 (50) 88 (30) ref ref
1 dose 0 (0) 28 (9) . . . . . .
2 doses 4 (50) 182 (61) 52 (−98, 88) 48 (−163, 90)
At least 1 dose 4 (50) 210 (70) 58 (−71, 90) 60 (−103, 92)
Data are presented as No. (%) unless otherwise specified.
Abbreviations: CI, confidence interval; ref, reference; VE, vaccine effectiveness.
a Protection conferred 14 days after vaccine receipt.
b Adjusted for month and year of admission, month and year of birth, and clinic.
c All controls included in analysis.
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mild disease. All children in the study were aged ≤21 months,
with a median age of 8 months, so we were also not able to as-
sess waning immunity in this population.
In conclusion, we found that rotavirus vaccine may provide
better protection against severe disease compared with milder
disease, which is consistent with other research conducted in
the region, but there is need for a more robust evaluation to as-
certain a definitive estimate of rotavirus VE in Zambia.
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